Dr. Weimin Wang is one of the industry' s leading oligonucleotide chemists with close to 30 years of oligonucleotide research experience. Dr. Wang has been a key contributor to the RNA therapeutic industry for over 20 years with more than 60 scientific publications and patents related to RNAi therapeutics. Before founding SanegeneBio, Dr. Wang worked at Dicerna Pharmaceuticals (acquired by Novo Nordisk in 2021) as the Executive Director of Chemistry. His team pioneered Dicerna' s liver targeting GalXC technology as well as extrahepatic delivery platforms. Prior to joining Dicerna, Dr. Wang joined Merck & Co. through its $1.1 billion acquisition of Sirna, where he developed one of the first lipid nanoparticle delivery systems for nucleic acid therapeutics. During his tenure at Sirna, Merck and Dicerna, Dr. Wang had evaluated over 500 external opportunities for nucleic acid drug discovery and delivery technology, and had managed numerous major partnerships including Eli Lilly, Roche, Novo Nordisk, Boehringer Ingelheim, Alexion, etc.